BLAYLOCK RONALD E 4

What Happened

• Ronald E. Blaylock, a member of Pfizer's Board of Directors, was granted 7,686.539 deferred units on 2026-04-23. The units are reported at $26.67 each, for a total reported value of $205,000. This filing is an award/grant (derivative units), not an open-market purchase or sale.

Key Details

• Transaction date and terms: 2026-04-23; 7,686.539 units at $26.67 per unit; total $205,000. (Transaction code A — award/grant; derivative)
• Security type: Units that represent phantom shares of common stock (derivative instrument).
• Plan: Granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Settlement: These deferred units are settled in cash or common stock at the director’s election after the director’s retirement from the Board.
• Shares owned after transaction: Not reported on this Form 4.
• Filing timeliness: Report filed 2026-04-27 — appears timely (filed within the two-business-day Form 4 reporting window).

Context

• These are deferred compensation units for a non-employee director (common practice for board pay) and do not indicate an immediate market purchase or sale of Pfizer stock. Because they are phantom units settled later in cash or stock, they represent compensation rather than a direct equity stake change today.